Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Ketamine has demonstrated rapid antidepressant effects in patients with treatment-resistant depression (TRD); however, the safety and tolerability of ketamine in this population have not been fully described. Herein we report the largest study to date of the safety, tolerability, and acceptability of ketamine in TRD. METHOD: Data from 205 intravenous (IV) ketamine infusions (0.5 mg/kg over 40 minutes) in 97 participants with DSM-IV-defined major depressive disorder (MDD) were pooled from 3 clinical trials conducted between 2006 and 2012 at 2 academic medical centers. Safety and tolerability measures included attrition, adverse events (AEs), hemodynamic changes, and assessments of psychosis and dissociation. RESULTS: The overall antidepressant response rate, defined as a ≥ 50% improvement in Montgomery-Asberg Depression Rating Scale score, was 67% (65 of 97 participants). Four of 205 infusions (1.95%) were discontinued due to AEs. The overall attrition rate was 3.1% (3 of 97). In the first 4 hours after the infusion, the most common general AEs were drowsiness, dizziness, poor coordination, blurred vision, and feeling strange or unreal. Approximately one third of individuals experienced protocol-defined hemodynamic changes. Ketamine resulted in small but significant increases in psychotomimetic and dissociative symptoms (all P < .05). There were no cases of persistent psychotomimetic effects, adverse medical effects, or increased substance use in a subgroup of patients with available long-term follow-up information. CONCLUSIONS: In this relatively large group of patients with TRD, ketamine was safe and well tolerated. Further research investigating the safety of ketamine in severe and refractory depression is warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00419003, NCT00548964, and NCT00768430.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Minimal clinical research supports these findings, suggesting that risks of dependency are extremely low when ketamine is administered in a medical setting [158-160]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [160]
In the citing paper
“Wan et al. [14] reported higher transient BP increases (peak increase of 19.6/13.4 mmHg based on 205 ketamine infusions) [14].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [14]
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Self-citationZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Self-citation(2001) · PubMed · Cited by 780
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
“over 40 minutes), ketamine can lead to vestibular perturbations, including dizziness (Wan et al., 2015) and nausea/vomiting (Ghoneim et al.”
BackgroundKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Self-citationTargeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
Self-citationPrognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“It should be noted that the use of IV ketamine for TRD is off-label and there is currently a lack of data concerning the longer-term safety and efficacy of this approach (124, 131).”
BackgroundSelf-citationKetamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
“within 24 h) in patients with treatment-resistant MDD (TRD) (Zarate et al. 2006; Mathew et al. 2012; Murrough, 2012; Murrough et al. 2013a, b, Lapidus et al. 2014; Wan et al. 2014) and bipolar depression (Diazgranados et al.”
BackgroundInfluentialSelf-citationAntidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R., Calvo-Sánchez, E., Gutiérrez-Rojas, L., & Meana, J. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0519-3 · Cited by 280
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240
“Nine meta-analysis from depression trials (Fond et al., 2014; Coyle and Laws, 2015; Lee et al., 2015; McGirr et al., 2015; Parsaik et al., 2015; Romeo et al., 2015; Wan et al., 2015; Kishimoto et al., 2016; Xu et al., 2016) shows low frequency of serious adverse events in the short term (but see Short et al.”
BackgroundPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Pharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
NMDA Receptors in the Central Nervous System
Hansen, K. B., Yi, F., Perszyk, R. E., Menniti, F. S., & Traynelis, S. F. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7321-7_1 · Cited by 199
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Correia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Emerging drugs for the treatment of anxiety
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1049996 · Cited by 164
“Over the last decade, several small RCTs have provided evidence that ketamine results in a rapid antidepressant effect (e.g., within one day), even in patients with treatmentresistant depression (TRD) [71-74].”
BackgroundInfluentialSelf-citationGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
“, 2006), with about 50% to 70% exhibiting a variable duration of response (aan het Rot et al., 2010; Wan et al., 2015).”
BackgroundEsketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
“Comparatively, 24% of patients reported feeling ‘strange or unreal’ within 120 min of racemic IV ketamine infusion [78].”
BackgroundHimmerich, H., Kan, C., Au, K., & Treasure, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107667 · Cited by 137
Bobo, W. V., Vande Voort, J. L., Croarkin, P. E., Leung, J. G., Tye, S. J., & Frye, M. A. (2016) · Depression and Anxiety · doi:10.1002/da.22505 · Cited by 123
“Across multiple short-term clinical trials, ketamine was associated with mild and transient adverse effects, the most common of which included increases in blood pressure and heart rate, dry mouth, headache, anxiety, confusion, and dissociation.[41, 42, 45, 48, 60] In general, these adverse effects resolved within 2 h…”
BackgroundTowards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 129
Ketamine for treatment-resistant depression: recent developments and clinical applications
Schwartz, J., Murrough, J. W., & Iosifescu, D. V. (2016) · Evidence Based Mental Health · doi:10.1136/eb-2016-102355 · Cited by 117
“Multiple clinical trials suggest that a single low dose (0.5mg/kg) of IV ketamine results in a 50–70% response rate in patients with TRD.16 Additional research as shown that depressed patients can experience symptom relief as early as 2 h, and lasting up to 2 weeks after a single administration of IV ketamine.13 The w…”
BackgroundInfluentialSelf-citationIntravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
Cullen, K. R., Amatya, P., Roback, M. G., Albott, C. S., Westlund Schreiner, M., Ren, Y., Eberly, L. E., Carstedt, P., Samikoglu, A., Gunlicks-Stoessel, M., et al. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0030 · Cited by 117
“The average response rate in published studies testing ketamine for adult TRD is 67% (Wan et al. 2015), which is considerably higher than TRD interventions (e.g., the average response rate for transcranial magnetic stimulation is 45% (Conelea et al. 2017).”
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
“5 mg/kg) ketamine infusions in 97 participants found that ketamine was well tolerated and not associated with increased abuse potential or neuronal injury (Wan et al., 2015).”
BackgroundKetamine as a rapid-acting agent for suicidal ideation: A meta-analysis
Bartoli, F., Riboldi, I., Crocamo, C., Brita, C. D., Clerici, M., & Carrà, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.010 · Cited by 121
Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., et al. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970860 · Cited by 110
Administration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110
“…increased substance use was detected after long-term follow-up, yet systematic investigations on the addictive potential of ketamine in depressive patients is missing, as are studies on the potential long-term negative outcomes such as ketamine induced cystitis (Jhang et al. 2015; Wan et al. 2015).”
BackgroundInfluentialDakwar, E., Hart, C. L., Levin, F. R., Nunes, E. V., & Foltin, R. W. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.39 · Cited by 105
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Jelen, L. A., & Stone, J. M. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2020.1854194 · Cited by 124
“In longer-term follow-up data of depressed subjects receiving ketamine infusions in clinical trials, there was no evidence of ketamine abuse, increased drug cravings or substance abuse (Wan et al., 2015).”
BackgroundResultInfluentialCeban, F., Rosenblat, J. D., Kratiuk, K., Lee, Y. L., Rodrigues, N. B., Gill, H., Subramaniapillai, M., Nasri, F., Lui, L. M. W., Lipsitz, O., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00846-5 · Cited by 104
“Although TEAEs are frequently reported [4], they are not considered a major burden; individual clinical trials, as well as pooled data from multiple trials have demonstrated that only 1–5% of patients discontinue treatment on account of tolerability/safety reports [6, 7, 14, 16].”
BackgroundTherapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Jaso, B. A., Niciu, M. J., Iadarola, N. D., Lally, N., Richards, E. M., Park, M., Ballard, E. D., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160321123221 · Cited by 98
“Sinai and Baylor combined their datasets to perform a systematic safety and tolerability analysis from their psychoactive placebo (midazolam) and multiple infusion ketamine trials [46].”
Efficacy of ketamine therapy in the treatment of depression
Mandal, S., Sinha, V., & Goyal, N. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_484_18 · Cited by 106
Ketamine: a versatile tool for anesthesia and analgesia
Barrett, W. A., Buxhoeveden, M. R., & Dhillon, S. (2020) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000916 · Cited by 103
The promise of ketamine for treatment‐resistant depression: current evidence and future directions
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12646 · Cited by 89
Self-citationThe abuse liability of ketamine: A scoping review of preclinical and clinical studies
Le, T. T., Cordero, I. P., Jawad, M. Y., Swainson, J., Di Vincenzo, J. D., Jaberi, S., Phan, L., Lui, L. M. W., Ho, R., Rosenblat, J. D., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.035 · Cited by 82
Treating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84
“≥50% improvement in Montgomery–Åsberg Depression Rating Scale score) with the administration of intravenous ketamine among individuals with treatment resistant depression.(70) Moreover, ketamine has also demonstrated anti-suicide effects; although they appear to be largely modified by reduction of depressive symptom s…”
BackgroundZanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
“…for many of the acute adverse effects of (R,S)‐ketamine including motor incoordination, perception and sensory changes, and psychotomimetic properties, as well as rewarding/abuse potential (Krystal et al., 1994; Sassano‐ Higgins et al., 2016; Wan et al., 2015; Zanos, Moaddel, et al., 2018).”
BackgroundPharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
“CANMAT recommend ketamine as an experimental adjunctive agent in an academic setting but echoed caution against adverse reactions, potential abuse, and its efficacy long term (Fond et al., 2014b; Serafini et al., 2014a; Coyle and Laws, 2015; Wan et al., 2015).”
BackgroundExperimental medication treatment approaches for depression
Ionescu, D., & Papakostas, G. I. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.33 · Cited by 83
“Ketamine is generally well tolerated and safe when given as a single treatment for research purposes, 19 though questions remain about abuse potential, as well as transient psychotomimetic, sympathomimetic and dissociative side effects.”
BackgroundA New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
Novel Pharmacological Approaches to the Treatment of Depression
Elias, E., Zhang, A. Y., & Manners, M. T. (2022) · Life · doi:10.3390/life12020196 · Cited by 90
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Riva-Posse, P., Reiff, C. M., Edwards, J. A., Job, G. P., Galendez, G. C., Garlow, S. J., Saah, T. C., Dunlop, B. W., & McDonald, W. M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.025 · Cited by 70
Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future
Koek, R. J., Schwartz, H. N., Scully, S., Langevin, J., Spangler, S. L., Korotinsky, A., Jou, K., & Leuchter, A. F. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.015 · Cited by 81
Thomas, R. K., Baker, G., Lind, J., & Dursun, S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793104 · Cited by 69
Doherty, T., Wajs, E., Melkote, R., Miller, J., Singh, J. B., & Weber, M. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00699-4 · Cited by 68
Aust, S., Gärtner, M., Basso, L., Otte, C., Wingenfeld, K., Chae, W. R., Heuser-Collier, I., Regen, F., Cosma, N. C., van Hall, F., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.005 · Cited by 67
Zhang, M. W., Harris, K. M., & Ho, R. C. (2016) · BMC Medical Ethics · doi:10.1186/s12910-016-0087-3 · Cited by 65
“Some researchers have emphasised the safety of ketamine at sub-anaesthetic doses [18], and distinguish its effects from the high doses used by recreational users.”
BackgroundInfluentialKetamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subramanian, S., Haroutounian, S., Palanca, B. J. A., & Lenze, E. J. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120152 · Cited by 77
Prognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2020) · Focus · doi:10.1176/appi.focus.18205 · Cited by 62
Seo, M. K., Jeong, S., Seog, D.-H., Lee, J. A., Lee, J.-H., Lee, Y., McIntyre, R. S., Park, S. W., & Lee, J. G. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.089 · Cited by 60
Banov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019) · CNS Spectrums · doi:10.1017/s1092852919001238 · Cited by 66
Falk, E., Schlieper, D., van Caster, P., Lutterbeck, M. J., Schwartz, J., Cordes, J., Grau, I., Kienbaum, P., & Neukirchen, M. (2020) · BMC Palliative Care · doi:10.1186/s12904-019-0499-1 · Cited by 57
Grabski, M., Borissova, A., Marsh, B., Morgan, C. J. A., & Curran, H. V. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112629 · Cited by 55
Vidal, S., Gex-Fabry, M., Bancila, V., Michalopoulos, G., Warrot, D., Jermann, F., Dayer, A., Sterpenich, V., Schwartz, S., Vutskits, L., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000960 · Cited by 52
Rodrigues, N. B., McIntyre, R. S., Lipsitz, O., Lee, Y., Cha, D. S., Nasri, F., Gill, H., Lui, L. M. W., Subramaniapillai, M., Kratiuk, K., et al. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1776699 · Cited by 51
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15f10026 · Cited by 49
Rodrigues, N. B., McIntyre, R. S., Lipsitz, O., Lee, Y. L., Cha, D. S., Shekotikhina, M., Vinberg, M., Gill, H., Subramaniapillai, M., Kratiuk, K., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.119 · Cited by 57
Swainson, J., Klassen, L. J., Brennan, S., Chokka, P. R., Katzman, M. A., Tanguay, R. L., & Khullar, A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00897-2 · Cited by 54
“The usage of ketamine for depressive disorders has been extensively reviewed elsewhere [14, 15, 20–23], including its excellent safety and tolerability [24, 25].”
BackgroundKetamine in Major Depressive Disorder: Mechanisms and Future Perspectives
Shin, C., & Kim, Y.-K. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0236 · Cited by 42
Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 45
“52 Rodrigues et al 53 recently reaffirmed much of these findings, demonstrating tolerability with 5% of participants withdrawing from treatment due to adverse events.”
Self-citationCooper, M. D., Rosenblat, J. D., Cha, D. S., Lee, Y., Kakar, R., & McIntyre, R. S. (2017) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2016.1139747 · Cited by 41
“Determining strategies that may minimise the foregoing potential adverse events is of great relevance for several reasons including but not limited to the following: (1) ketamine is categorised as a dissociative anaesthetic and has been identified as a drug of abuse; however, evidence from clinical research settings s…”
BackgroundOughli, H. A., Gebara, M. A., Ciarleglio, A., Lavretsky, H., Brown, P. J., Flint, A. J., Farber, N. B., Karp, J. F., Mulsant, B. H., Reynolds, C. F., et al. (2022) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.11.013 · Cited by 43
Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression
McMullen, E. P., Lee, Y. L., Lipsitz, O., Lui, L. M. W., Vinberg, M., Ho, R., Rodrigues, N. B., Rosenblat, J. D., Cao, B., Gill, H., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01732-8 · Cited by 60
Personalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 51
Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice
Lin, J.-C., Lee, M.-Y., Chan, M., Chen, Y.-C., & Chen, H. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4359-x · Cited by 43
Sex- and dose-dependent abuse liability of repeated subanesthetic ketamine in rats
Schoepfer, K. J., Strong, C. E., Saland, S. K., Wright, K. N., & Kabbaj, M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.10.021 · Cited by 39
Chen, Q., Min, S., Hao, X., Peng, L., Meng, H., Luo, Q., Chen, J., & Li, X. (2017) · The Journal of ECT · doi:10.1097/yct.0000000000000365 · Cited by 37
“5 mg per kilogram body weight) are administered once or repeatedly.(13,14) In addition, it is speculated that ketamine, as an N-methyl-D-aspartate receptor antagonist, can reduce the ECT-induced excitotoxic neuronal damage and further alleviate learning and memory impairments.”
BackgroundMethodAntidepressant effects of ketamine and ECT: A pilot comparison
Sharma, R. K., Kulkarni, G., Kumar, C. N., Arumugham, S. S., Venkataramaiah, S., Mehta, U. M., Mitra, S., Thanki, M. V., & Thirthalli, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.066 · Cited by 41
Scotton, E., Antqueviezc, B., Vasconcelos, M., Dalpiaz, G., Géa, L. P., Goularte, J. F., Colombo, R., & Rosa, A. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114963 · Cited by 40
Ketamine‐An Update on Its Clinical Uses and Abuses
Xu, J., & Lei, H. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12363 · Cited by 37
Advances in Pharmacotherapy of Late-Life Depression
Beyer, J. L., & Johnson, K. G. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0899-6 · Cited by 41
Maintenance Ketamine Therapy for Treatment-Resistant Depression
Archer, S., Chrenek, C., & Swainson, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000894 · Cited by 34
Ketamine for depression clinical issues
Iqbal, S., & Mathew, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.02.005 · Cited by 40
Self-citationSydnor, V. J., Lyall, A. E., Karayumak, S. C., Cheung, J. C., Felicione, J. M., Akeju, O., Shenton, M. E., Deckersbach, T., Ionescu, D. F., Pasternak, O., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01122-8 · Cited by 32
Ketamine for Treatment-Resistant Depression
Zarate Jr, C. A., & Mathew, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0 · Cited by 38
Self-citationEmerging evidence for antidepressant actions of anesthetic agents
Tadler, S. C., & Mickey, B. J. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000617 · Cited by 31
Yao, Y., Ju, P., Liu, H., Wu, X., Niu, Z., Zhu, Y., Zhang, C., & Fang, Y. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05469-0 · Cited by 33
“Ketamine has superior effects in rapidly alleviating the symptoms of MDD patients symptoms compared with traditional antidepressants that modulate the monoaminergic system (Archer et al. 2018; Salloum et al. 2019; Schoevers et al. 2016; Wan et al. 2015).”
BackgroundKetamine: stimulating antidepressant treatment?
Malhi, G. S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M. A., Gitlin, M., Kennedy, S. H., Ketter, T. A., Lam, R. W., et al. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002923 · Cited by 29
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
Henter, I. D., SOUSA, R. T. D., Gold, P. W., Brunoni, A. R., Zarate, C. A., & Machado‐Vieira, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1253472 · Cited by 32
“5 mg/kg) across three clinical trials at two centers [23].”
BackgroundHighland, K. B., Soumoff, A. A., Spinks, E. A., Kemezis, P. A., & Buckenmaier, C. C. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004327 · Cited by 28
Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine
Zavaliangos‐Petropulu, A., Al‐Sharif, N., Taraku, B., Leaver, A. M., Sahib, A. K., Espinoza, R. T., & Narr, K. L. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2022.11.005 · Cited by 40
Chrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R. K., & Swainson, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1283733 · Cited by 29
“Common side effects noted in literature are transient and may include psychotomimetic and dissociative experiences, blurred vision, dizziness, anxiety, irritability, headaches, nausea, tachycardia, and elevated blood pressure (6, 49, 50).”
BackgroundPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 31
Self-citationPharmacotherapy of major depression in late life: what is the role of new agents?
Patel, K., Abdool, P. S., Rajji, T. K., & Mulsant, B. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1308484 · Cited by 29
The Risk of Upper Urinary Tract Involvement in Patients With Ketamine-Associated Uropathy
Yee, C., Teoh, J. Y., Lai, P.-T., Leung, V. Y.-F., Chu, C. W., Lee, W., Tam, Y.-H., & Ng, C. (2017) · International Neurourology Journal · doi:10.5213/inj.1732704.352 · Cited by 25
“depression [3], and bipolar affective disorder [4].”
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P., & Robison, R. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04268-5 · Cited by 24
“95% of IV ketamine infusions which were discontinued due to AEs as reported in a 2015 systematic review and meta-analysis [49].”
BackgroundAlmeida, T. M., da Silva, U. R. L., Pires, J. P., Borges, I. N., Martins, C. R. M., Cordeiro, Q., & Uchida, R. R. (2024) · PubMed Central · doi:10.36131/cnfioritieditore20240102 · Cited by 51
“These data are consistent with previous studies that have assessed the safety and tolerability of ketamine (Wan et al., 2015; Vázquez et al., 2021).”
ResultLascelles, K. M., Marzano, L., Brand, F., Trueman, H., McShane, R. H., & Hawton, K. E. (2020) · BJPsych Open · doi:10.1192/bjo.2020.132 · Cited by 25
Ludwig, V. M., Sauer, C., Young, A. H., Rucker, J., Bauer, M., Findeis, H., & Ritter, P. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00837-6 · Cited by 24
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 26
ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice
Shen, M., Lv, D., Liu, X., & Wang, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02290-5 · Cited by 22
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior
Mallick, F., & McCullumsmith, C. B. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0680-7 · Cited by 22
Refsgaard, L. K., Pickering, D. S., & Andreasen, J. T. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000266 · Cited by 22
“…this early after treatment and considering that many of the responding individuals were defined as treatment resistant, that is, not responding to conventional monoamine-based antidepressants (Mathew et al., 2010; Murrough, 2012; Murrough et al., 2013; Salvadore and Singh, 2013; Wan et al., 2015).”
BackgroundKetamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders
Samojedny, S., Czechowska, E., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911423 · Cited by 23
“5 mg/kg/40 min; performed 2006 and 2012) showed antidepressant activity (improvement in Montgomery–Asberg Depression Rating Scale (MADRS) scores) in 67% of TRD individuals [195].”
BackgroundCurrent Status of Ketamine and Related Therapies for Mood and Anxiety Disorders
Costi, S., Dam, N. T. V., & Murrough, J. W. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0052-3 · Cited by 21
“A recent work byWan and colleagues [78] analyzed the safety and tolerability from 205 patient infusions of ketamine conducted at a single center.”
BackgroundSelf-citationA regulatory perspective on the evaluation of hallucinogen drugs for human use
Calderon, S. N., Hunt, J., & Klein, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.028 · Cited by 25
Feng, M., Crowley, N. A., Patel, A., Guo, Y., Bugni, S. E., & Luscher, B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.003 · Cited by 20
“More than half of these patients show rapid and lasting improvements following treatment with ketamine, a rapidly acting experimental treatment that is increasingly available to otherwise treatment-resistant patients (Murrough et al., 2013a; Wan et al., 2015).”
BackgroundGeneral Anesthetics to Treat Major Depressive Disorder: Clinical Relevance and Underlying Mechanisms
Vutskits, L. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002594 · Cited by 25
Intranasal esketamine: A novel drug for treatment-resistant depression
Khorassani, F., & Talreja, O. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa191 · Cited by 21
Metadata
- Authors
- Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W.
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-09-02
- Volume
- 76
- Issue
- 03
- Pages
- 247-252
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2059761623
- Cited by
- 231
- References
- 34
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 15 · 2023: 14 · 2022: 36 · 2021: 21 · 2020: 36 · 2019: 18 · 2018: 15 · 2017: 14 · 2016: 23 · 2015: 15 · 2014: 1
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000067)
- National Institute of Mental Health (R01MH081870, K23MH094707)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, treatment-resistant depression, major depressive disorder, drug safety, tolerability, adverse events, psychotomimetic effects, dissociation, hemodynamic changes, antidepressant response, attrition, intravenous infusion
- MeSH terms
- Adult, Clinical Trials as Topic, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Treatment Outcome, Excitatory Amino Acid Antagonists, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.